论文部分内容阅读
目的探讨布地奈德/福莫特罗粉剂联合噻托溴铵治疗慢性阻塞性肺疾病稳定期的疗效。方法 80例慢性阻塞性肺疾病稳定期患者根据患者意愿分为观察组与参考组,各40例,观察组患者采用布地奈德/福莫特罗粉剂联合噻托溴铵治疗,参考组仅采用布地奈德/福莫特罗粉剂治疗,观察两组患者治疗前后动脉血气指标、肺功能改善情况,比较患者治疗期间不良反应的发生情况及治疗后生活质量评分。结果治疗后两组患者动脉血气指标及肺功能均得到明显改善(P<0.05),观察组改善情况明显优于参考组(P<0.05),观察组与参考组患者治疗期间均未出现严重不良反应(P>0.05)。结论布地奈德/福莫特罗粉剂联合噻托溴铵治疗慢性阻塞性肺疾病稳定期能够有效改善患者肺功能,缓解临床症状,同时安全性高,值得临床推广应用。
Objective To investigate the efficacy of budesonide / formoterol powder combined with tiotropium in the treatment of chronic obstructive pulmonary disease (COPD) at stable stage. Methods Eighty patients with stable chronic obstructive pulmonary disease (COPD) were divided into observation group (40 cases) and reference group (40 cases) according to their wishes. The patients in observation group were treated with budesonide / formoterol powder combined with tiotropium, while the reference group Budesonide / formoterol powder treatment, arterial blood gas index before and after treatment in both groups were observed, the improvement of pulmonary function, the incidence of adverse reactions during treatment and quality of life after treatment were compared. Results After treatment, the arterial blood gas index and pulmonary function were significantly improved in both groups (P <0.05), and the improvement in the observation group was significantly better than that in the reference group (P <0.05). No significant adverse reactions occurred in the observation group and the reference group Reaction (P> 0.05). Conclusion The combination of budesonide and formoterol powder and tiotropium in the treatment of chronic obstructive pulmonary disease (COPD) can effectively improve the lung function and relieve the clinical symptoms in patients with chronic obstructive pulmonary disease. It is safe and worthy of clinical application.